| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group.
|
Blood
|
2003
|
2.27
|
|
2
|
Landscape of somatic mutations and clonal evolution in mantle cell lymphoma.
|
Proc Natl Acad Sci U S A
|
2013
|
2.00
|
|
3
|
SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia.
|
Blood
|
2009
|
1.76
|
|
4
|
Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group.
|
Blood
|
2008
|
1.68
|
|
5
|
Identification of overexpressed genes in frequently gained/amplified chromosome regions in multiple myeloma.
|
Haematologica
|
2006
|
1.65
|
|
6
|
Cytogenetic risk stratification in chronic myelomonocytic leukemia.
|
Haematologica
|
2010
|
1.60
|
|
7
|
Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.
|
Haematologica
|
2009
|
1.39
|
|
8
|
Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma.
|
Blood
|
2002
|
1.38
|
|
9
|
Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia.
|
Haematologica
|
2011
|
1.30
|
|
10
|
A novel gene, MDS2, is fused to ETV6/TEL in a t(1;12)(p36.1;p13) in a patient with myelodysplastic syndrome.
|
Genes Chromosomes Cancer
|
2002
|
1.01
|
|
11
|
Molecular heterogeneity in AML/MDS patients with 3q21q26 rearrangements.
|
Genes Chromosomes Cancer
|
2004
|
0.94
|
|
12
|
Interphase FISH assays for the detection of translocations with breakpoints in immunoglobulin light chain loci.
|
Int J Cancer
|
2002
|
0.94
|
|
13
|
Integration of SNP and mRNA arrays with microRNA profiling reveals that MiR-370 is upregulated and targets NF1 in acute myeloid leukemia.
|
PLoS One
|
2012
|
0.92
|
|
14
|
TP53 is frequently altered by methylation, mutation, and/or deletion in acute lymphoblastic leukaemia.
|
Mol Carcinog
|
2003
|
0.90
|
|
15
|
Methylation of CpG dinucleotides and/or CCWGG motifs at the promoter of TP53 correlates with decreased gene expression in a subset of acute lymphoblastic leukemia patients.
|
Oncogene
|
2003
|
0.88
|
|
16
|
Clinical variability of patients with the t(6;8)(q27;p12) and FGFR1OP-FGFR1 fusion: two further cases.
|
Hematol J
|
2004
|
0.86
|
|
17
|
Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia.
|
Haematologica
|
2011
|
0.86
|
|
18
|
NUP98 is fused to adducin 3 in a patient with T-cell acute lymphoblastic leukemia and myeloid markers, with a new translocation t(10;11)(q25;p15).
|
Cancer Res
|
2003
|
0.86
|
|
19
|
Silencing of hsa-miR-124 by EVI1 in cell lines and patients with acute myeloid leukemia.
|
Proc Natl Acad Sci U S A
|
2010
|
0.86
|
|
20
|
t(10;16)(q22;p13) and MORF-CREBBP fusion is a recurrent event in acute myeloid leukemia.
|
Genes Chromosomes Cancer
|
2003
|
0.85
|
|
21
|
Methylation status of SOCS1 and SOCS3 in BCR-ABL negative and JAK2V617F negative chronic myeloproliferative neoplasms.
|
Leuk Res
|
2008
|
0.84
|
|
22
|
p53 Aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV.
|
Br J Haematol
|
2005
|
0.84
|
|
23
|
NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder.
|
Cancer Res
|
2004
|
0.84
|
|
24
|
Reciprocal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemias: review of 5,654 patients with an evaluable karyotype.
|
Genes Chromosomes Cancer
|
2013
|
0.83
|
|
25
|
Interphase FISH for the detection of breakpoints in IG loci and chromosomal changes with adverse prognostic impact in multiple myeloma with normal karyotypes.
|
Cancer Genet Cytogenet
|
2006
|
0.82
|
|
26
|
Molecular characterization of a t(1;3)(p36;q21) in a patient with MDS. MEL1 is widely expressed in normal tissues, including bone marrow, and it is not overexpressed in the t(1;3) cells.
|
Oncogene
|
2004
|
0.81
|
|
27
|
Downregulation of PPP2R5E is a common event in acute myeloid leukemia that affects the oncogenic potential of leukemic cells.
|
Haematologica
|
2013
|
0.80
|
|
28
|
Geographic differences in the incidence of cytogenetic abnormalities of acute myelogenous leukemia (AML) in Spain.
|
Leuk Res
|
2006
|
0.80
|
|
29
|
Identification of recurrent chromosomal breakpoints in multiple myeloma with complex karyotypes by combined G-banding, spectral karyotyping, and fluorescence in situ hybridization analyses.
|
Cancer Genet Cytogenet
|
2006
|
0.79
|
|
30
|
Characterization and prognostic implication of 17 chromosome abnormalities in myelodysplastic syndrome.
|
Leuk Res
|
2013
|
0.77
|
|
31
|
Multicolor interphase cytogenetics for the study of plasma cell dyscrasias.
|
Oncol Rep
|
2007
|
0.77
|
|
32
|
NUP98 is fused to HOXA9 in a variant complex t(7;11;13;17) in a patient with AML-M2.
|
Cancer Genet Cytogenet
|
2005
|
0.76
|
|
33
|
FISH analysis of hematological neoplasias with 1p36 rearrangements allows the definition of a cluster of 2.5 Mb included in the minimal region deleted in 1p36 deletion syndrome.
|
Hum Genet
|
2005
|
0.76
|
|
34
|
Refining the Breakpoints of Three New Translocations Identified in Myelodysplastic Syndromes.
|
Acta Haematol
|
2015
|
0.75
|
|
35
|
Molecular cytogenetic characterization of breakpoints in 19 patients with hematologic malignancies and 12p unbalanced translocations.
|
Cancer Genet Cytogenet
|
2003
|
0.75
|
|
36
|
Coexistence of different clonal populations harboring the b3a2 (p210) and e1a2 (p190) BCR-ABL1 fusion transcripts in chronic myelogenous leukemia resistant to imatinib.
|
Cancer Genet Cytogenet
|
2005
|
0.75
|
|
37
|
Simultaneous translocations of FGFR3/MMSET and CCND1 into two different IGH alleles in multiple myeloma: lack of concurrent activation of both proto-oncogenes.
|
Cancer Genet Cytogenet
|
2007
|
0.75
|
|
38
|
Quantification of PDGFRA alternative transcripts improves the screening for X-PDGFRA fusions by reverse transcriptase-polymerase chain reaction.
|
Leuk Lymphoma
|
2010
|
0.75
|
|
39
|
Lack of association of CYP3A4-V polymorphism with the risk of treatment-related leukemia.
|
Leuk Res
|
2005
|
0.75
|
|
40
|
Remission of acute monocytic leukemia, secondary to treatment with epipodophyllotoxins, in a patient with t(8;16)(p11;p13) and MYST3-CREBBP fusion.
|
Cancer Genet Cytogenet
|
2004
|
0.75
|